Drug intelligence / Profile preview

OCNR-300

Development stage: Preclinical
Lead developer: Onconic Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

OCNR-300 is an early-stage, preclinical small molecule drug candidate being developed by Onconic Therapeutics for the treatment of solid tumors. It is designed as a dual-targeted agent that exploits synthetic lethality by targeting the DNA damage response (DDR) pathway. Currently in the proof-of-concept (PoC) and hit-to-lead generation phase, OCNR-300 aims to address resistance to conventional PARP inhibitors and selectively induce cancer cell death.

Beyond the preview

Go deeper on OCNR-300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCNR-300.

Explore the full profile